Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXL770 drug-drug interaction study with repaglinide, tolbutamide, midazolam, and caffeine in healthy volunteers
NL-OMON50829Completed
- Sponsor
- Poxel SA
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of PXL770 in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) (4 arms), sponsored by Poxel SA. Primary endpoint: Effect of repeated PXL770 on primary pharmacokinetic parameters of probe drugs. Started Apr 2021; status: completed.
02
Drugs
PXL770
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NL-OMON50829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50829.